Collegium Pharmaceutical (COLL) Change in Account Payables (2014 - 2026)

Collegium Pharmaceutical's Change in Account Payables history runs 13 years deep, the most recent figure standing at -$3.8 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 127.49% year-over-year to -$3.8 million in Q1 2026; TTM through Mar 2026 was -$11.0 million, a 313.02% decrease from a year earlier, with the FY2025 full-year figure at $6.7 million, up 159.57% from the prior year.
• Change in Account Payables retreated to -$3.8 million in Q1 2026 per COLL's latest filing, from $3.0 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $13.9 million in Q1 2025 and bottomed at -$7.0 million in Q2 2025.
• The 5-year median for Change in Account Payables is -$502000.0 (2023), against an average of -$237235.3.
• Across the five-year window, Change in Account Payables slumped 603.3% in 2024 and surged 648.86% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at -$4.1 million in 2022, then jumped by 219.6% to $5.0 million in 2023, then slumped by 83.65% to $810000.0 in 2024, then surged by 275.93% to $3.0 million in 2025, then tumbled by 225.68% to -$3.8 million in 2026.
• Per Business Quant, the three latest COLL Change in Account Payables figures stand at -$3.8 million (Q1 2026), $3.0 million (Q4 2025), and -$3.3 million (Q3 2025).